Abstract
Sarcopenia, the progressive loss of muscle mass with age, is characterized by a deterioration of muscle quantity and quality leading to a gradual slowing of movement and a decline in strength and power. Sarcopenia is a highly significant public health problem. Since these age-related changes in skeletal muscle are largely attributed to various molecular mediators affecting fiber size, mitochondrial homeostatis, and apoptosis, the mechanisms responsible for these deleterious changes present numerous therapeutic targets for drug discovery. We and other researchers demonstrated that a disruption of Akt-mTOR and RhoA-SRF signaling but not Atrogin-1 or MuRF1 contributes to sarcopenia. In addition, sarcopenia seems to include a marked loss of fibers attributable to apoptosis. This review deals with molecular mechanisms of muscle atrophy and provides an update on current strategies (resistance training, myostatin inhibition, treatment with amino acids or testosterone, calorie restriction, etc) for counteracting this loss. Resistance training in combination with amino acid-containing nutrition would be the best candidate to attenuate, prevent, or ultimately reverse age-related muscle wasting and weakness.
Keywords: Sarcopenia, SRF, testosterone, myostatin, skeletal muscle
Current Aging Science
Title: Molecular Mechanisms in Aging and Current Strategies to Counteract Sarcopenia
Volume: 3 Issue: 2
Author(s): Kunihiro Sakuma and Akihiko Yamaguchi
Affiliation:
Keywords: Sarcopenia, SRF, testosterone, myostatin, skeletal muscle
Abstract: Sarcopenia, the progressive loss of muscle mass with age, is characterized by a deterioration of muscle quantity and quality leading to a gradual slowing of movement and a decline in strength and power. Sarcopenia is a highly significant public health problem. Since these age-related changes in skeletal muscle are largely attributed to various molecular mediators affecting fiber size, mitochondrial homeostatis, and apoptosis, the mechanisms responsible for these deleterious changes present numerous therapeutic targets for drug discovery. We and other researchers demonstrated that a disruption of Akt-mTOR and RhoA-SRF signaling but not Atrogin-1 or MuRF1 contributes to sarcopenia. In addition, sarcopenia seems to include a marked loss of fibers attributable to apoptosis. This review deals with molecular mechanisms of muscle atrophy and provides an update on current strategies (resistance training, myostatin inhibition, treatment with amino acids or testosterone, calorie restriction, etc) for counteracting this loss. Resistance training in combination with amino acid-containing nutrition would be the best candidate to attenuate, prevent, or ultimately reverse age-related muscle wasting and weakness.
Export Options
About this article
Cite this article as:
Sakuma Kunihiro and Yamaguchi Akihiko, Molecular Mechanisms in Aging and Current Strategies to Counteract Sarcopenia, Current Aging Science 2010; 3 (2) . https://dx.doi.org/10.2174/1874609811003020090
DOI https://dx.doi.org/10.2174/1874609811003020090 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Towards Environmental Construct Validity in Animal Models of CNS Disorders: Optimizing Translation of Preclinical Studies
CNS & Neurological Disorders - Drug Targets Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science Alzheimer´s Disease and Oxidative Stress: A Review
Current Medicinal Chemistry Elevated Levels of Bilirubin and Long-Term Exposure Impair Human Brain Microvascular Endothelial Cell Integrity
Current Neurovascular Research Telomeric Repeat Containing RNA (TERRA): Aging and Cancer
CNS & Neurological Disorders - Drug Targets Activities of Venom Proteins and Peptides with Possible Therapeutic Applications from Bees and WASPS
Protein & Peptide Letters Aluminum Induced Immunoexcitotoxicity in Neurodevelopmental and Neurodegenerative Disorders
Current Inorganic Chemistry (Discontinued) Old Friends in New Constellations - the Hematopoetic Growth Factors G-CSF, GMCSF, and EPO for the Treatment of Neurological Diseases
Current Medicinal Chemistry Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry A Glimpse of Matrix Metalloproteinases in Diabetic Nephropathy
Current Medicinal Chemistry Neuroprotective Role of Natural Polyphenols
Current Topics in Medicinal Chemistry Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases
Current Molecular Medicine Meet Our Regional Editor
CNS & Neurological Disorders - Drug Targets DNA Secondary Structure at Chromosomal Fragile Sites in Human Disease
Current Genomics Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets Induced Pluripotent Stem Cells and Their Potential for Basic and Clinical Sciences
Current Cardiology Reviews Tracking Stem Cells for Cellular Therapy in Stroke
Current Pharmaceutical Design Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology Inhibition of Human Serine Racemase, an Emerging Target for Medicinal Chemistry
Current Drug Targets Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design